VOR
NASD Vor Biopharma, Inc.$18.77 ↓ -0.31 (-1.62%) Trading Down from the previous close of $19.08, $0.53 below the day’s high of $19.30
- YTD change
- +43.50%
- vs 20-day SMA
- -13.42%
- vs 200-day SMA
- +12.34%
Price ranges
Price & Performance
+1.69 (+9.72%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 98.5% away from all-time highs of $1,272.40
- VOR is up 44% since the beginning of the year
- VOR is down 52% over the past 12 months
- VOR is down 17% over the past 1 month
- 15% of all VOR investors are betting against VOR
VOR reads not so good: price sits above one of the two key moving averages, the 12-month move is -51.4%.
- Previous minute
- +$0.06
- Last hour
- +$0.09
- Last 5 days
- -3.10%
- vs 8-day SMA
- -3.71%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Vor Biopharma, Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. It is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
